Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.20.2
Commitments and Contingencies (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2019
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2020
GBP (£)
Sep. 30, 2019
USD ($)
Jan. 31, 2018
USD ($)
Commitments and Contingencies (Details) [Line Items]              
Upfront payments             $ 25,000
Annual fees       $ 30,000      
Included under research expensed   $ 4,000   4,000      
Product candidates   4,000 $ 21,000 5,000   $ 221,000  
Research and development expense           21,000  
Prepaid expense   6,000   6,000      
Approximately payable   71,000   71,000      
Other current assets   65,000   $ 65,000      
Research and development expenses not exceeding GBP (in Pounds) | £         £ 24,215    
Patents [Member]              
Commitments and Contingencies (Details) [Line Items]              
Net revenue, percentage       50.00% 50.00%    
LP-184 [Member]              
Commitments and Contingencies (Details) [Line Items]              
Annual fees       $ 30,000      
AF Chemicals [Member]              
Commitments and Contingencies (Details) [Line Items]              
Commitments and contingencies, description       the ability for the Company to pay AF Chemicals additional amounts ranging from $25,000 to $50,000 for each one, two, and three year extension to such development time requirements, with additional extensions beyond three years to be negotiated by the Company and AF Chemicals. During the three and nine months ended September 30, 2020, the Company paid AF Chemicals $0 and $50,000, respectively, relating to the IND filing milestone extension fee for LP-184, $12,500 and $37,500 of which were expensed during the three and nine months ended September 30, 2020, respectively, and included under research and development expenses in the accompanying condensed consolidated statements of operations. The Company paid AF Chemicals $37,500 during the year ended December 31, 2019 in connection with extension of the IND filing milestone for LP-184, $37,500 of which was paid during the three and nine months ended September 30, 2019. Amounts of $9,375 and $28,125 were expensed during the three and nine months ended September 30, 2019, respectively, related to this extension payment, and included under research and development expenses in the accompanying condensed consolidated statements of operations. the ability for the Company to pay AF Chemicals additional amounts ranging from $25,000 to $50,000 for each one, two, and three year extension to such development time requirements, with additional extensions beyond three years to be negotiated by the Company and AF Chemicals. During the three and nine months ended September 30, 2020, the Company paid AF Chemicals $0 and $50,000, respectively, relating to the IND filing milestone extension fee for LP-184, $12,500 and $37,500 of which were expensed during the three and nine months ended September 30, 2020, respectively, and included under research and development expenses in the accompanying condensed consolidated statements of operations. The Company paid AF Chemicals $37,500 during the year ended December 31, 2019 in connection with extension of the IND filing milestone for LP-184, $37,500 of which was paid during the three and nine months ended September 30, 2019. Amounts of $9,375 and $28,125 were expensed during the three and nine months ended September 30, 2019, respectively, related to this extension payment, and included under research and development expenses in the accompanying condensed consolidated statements of operations.    
Expenses           22,500  
milestone extension paid   25,000   $ 25,000      
AF Chemicals [Member] | LP-184 [Member]              
Commitments and Contingencies (Details) [Line Items]              
Expenses   7,500   22,500      
LP-100 [Member] | AF Chemicals [Member]              
Commitments and Contingencies (Details) [Line Items]              
Annual fees   0 7,500     0  
Expenses       $ 30,000   $ 30,000  
EU Grant [Member]              
Commitments and Contingencies (Details) [Line Items]              
Research and development expenses percentage       50.00% 50.00%    
Patheon API Services [Member]              
Commitments and Contingencies (Details) [Line Items]              
Manufacturing agreement, description           The Company paid approximately $194,000 to Patheon during the three months ended September 30, 2020 pursuant to the Patheon agreement. Approximately $78,000 was expensed with respect to the Patheon agreement during the three months ended September 30, 2020, which represents the services received by the Company through September 30, 2020. This amount is included in research and development expenses in the accompanying condensed consolidated statements of operations. Approximately $116,000 relating to the Patheon agreement is included under prepaid expenses on the Company’s condensed consolidated balance sheet for the period ended September 30, 2020. The Company expects to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under the Patheon agreement.  
Southwest Research Institute [Member]              
Commitments and Contingencies (Details) [Line Items]              
Research and development expense       $ 99,000      
Prepaid expense   97,000   97,000      
Operating Lease [Member]              
Commitments and Contingencies (Details) [Line Items]              
Lease term, description the Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The lease expired on July 31, 2020 and was not renewed.            
AF Chemicals [Member] | LP-184 [Member]              
Commitments and Contingencies (Details) [Line Items]              
Annual fees   0 0 30,000   $ 30,000  
Expenses     $ 7,500     $ 22,500  
BioNumerik Pharmaceutical [Member]              
Commitments and Contingencies (Details) [Line Items]              
Upfront payments   25,000   $ 25,000      
Commitments and contingencies, description       In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion. In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.    
Amounts payable   11,000   $ 11,000      
LP-100 [Member] | AF Chemicals [Member]              
Commitments and Contingencies (Details) [Line Items]              
Annual fees   $ 7,500          
Expenses       $ 22,500